Regulus Therapeutics reported $-7551000 in Net Income for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Alnylam Pharmaceuticals ALNY:US USD -405920000 128.52M
Astrazeneca AZN:US USD 1.64B 1.28B
AstraZeneca AZN:LN USD 1.64B 1.28B
Biogen BIIB:US USD 1.13B 76.7M
Gilead Sciences GILD:US USD 1.79B 645M
GlaxoSmithKline GSK:LN GBP 10.32B 9.48B
Intercept Pharmaceuticals ICPT:US USD 267.45M 274.98M
Intrexon XON:US USD 87.38M 105.01M
Merk MRK:US USD 3.25B 696M
Omeros OMER:US USD -17456000 13.39M
Regulus Therapeutics RGLS:US USD -7551000 293K
Sangamo Biosciences SGMO:US USD -53155000 9.98M
Takeda 4502:JP JPY 61.74B 43.27B
Vital Therapies VTL:US USD -21224000 677K
YTE INCY:US USD 112.78M 48.66M